RIGI and cancer: The concomitant repression of RISC components DICER, AGO2, and TRBP2 and the induction of dsRNA sensors RIG-I and MDA5 lead to the activation of Type I and III Interferon responses and could be exploited to overcome cancer resistance to immune checkpoint blockage (142).